Aprea Therapeutics, Inc. (APRE)

NCM – Цена в реальном времени. Валюта: USD

0.79

+0.00 (0.04%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

0.79

0.00 (0.00%)

После закрытия: Jun 26, 2026, 4:10 PM EDT

01.06.2026

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types Manageable tolerability confirmed across cohorts Patient expansion into uterine serous carcinoma and platinum-resistant ovarian cancer underway; dose escalation and backfill expansion expected to complete Q2 2027 DOYLESTOWN, Pa., June 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, announces the presentation of a poster “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” on May 30 at the American Society of Clinical Oncology (ASCO) 2026 annual meeting, taking place in Chicago, Illinois.

21.05.2026

Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know

Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

13.05.2026

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

21.04.2026

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 - June 2, 2026, in Chicago, IL.

01.04.2026

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the closing of its previously announced oversubscribed private placement financing.

30.03.2026

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $30 million to the Company before deducting placement agent fees and other private placement expenses (the “Offering”).

30.03.2026

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancers Early clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitor Emerging clinical proof of concept responses without class-limiting toxicity to date support Aprea's development strategy of differentiated WEE1 inhibition with an improved therapeutic index A further update from the trial is expected in the second quarter of 2026 DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the confirmation of a partial response (PR) in its ongoing ACESOT-1051 trial evaluating APR-1051, a potent and selective WEE1 kinase inhibitor.

Видео

No Data

There is no data to display

Пресс-релизы

01.06.2026

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

13.05.2026

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

21.04.2026

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

01.04.2026

Aprea Therapeutics, Inc. (APRE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Aprea Therapeutics, Inc. (APRE)

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Видео

No Data

Пресс-релизы

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Видео

No Data

Пресс-релизы

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Search stocks

Aprea Therapeutics, Inc. (APRE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Aprea Therapeutics, Inc. (APRE)

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Видео

No Data

Пресс-релизы

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Видео

No Data

Пресс-релизы

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement